Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2

Author:

Petter Ella,Mor Orna,Zuckerman Neta,Oz-Levi Danit,Younger Asaf,Aran Dvir,Erlich Yaniv

Abstract

AbstractOne of the key questions regarding COVID19 vaccines is whether they can reduce viral shedding. To date, Israel vaccinated substantial parts of the adult population, which enables extracting real world signals. The vaccination rollout started on Dec 20th 2020, utilized mainly the BNT162b2 vaccine, and focused on individuals who are 60 years or older. By now, more than 75% of the individuals of this age group have been at least 14 days after the first dose, compared to 25% of the individuals between ages 40-60 years old. Here, we traced the Ct value distribution of 16,297 positive qPCR tests in our lab between Dec 1st to Jan 31st that came from these two age groups. As we do not have access to the vaccine status of each test, our hypothesis was that if vaccines reduce viral load, we should see a difference in the Ct values between these two age groups in late January but not before. Consistent with this hypothesis, until Jan 15th, we did not find any statistically significant differences in the average Ct value between the groups. In stark contrast, our results in the last two weeks of January show a significant weakening in the average Ct value of 60+ individuals to the 40-60 group. To further corroborate these results, we also used a series nested linear models to explain the Ct values of the positive tests. This analysis favored a model that included an interaction between age and the late January time period, consistent with the effect of vaccination. We then used demographic data and the daily vaccination rates to estimate the effect of vaccination on viral load reduction. Our estimate suggests that vaccination reduces the viral load by 1.6x to 20x in individuals who are positive for SARS-CoV-2. This estimate might improve after more individuals receive the second dose. Taken together, our findings indicate vaccination is not only important for individual’s protection but can reduce transmission.

Publisher

Cold Spring Harbor Laboratory

Reference10 articles.

1. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

2. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

3. What can we expect from first-generation COVID-19 vaccines?;Lancet,2020

4. M. Voysey , S. A. Costa Clemens , S. A. Madhi , L. Y. Weckx , P. M. Folegatti , P. K. Aley , B. J. Angus , V. Baillie , S. L. Barnabas , Q. E. Bhorat , S. Bibi , C. Briner , P. Cicconi , E. Clutterbuck , A. M. Collins , C. Cutland , T. Darton , K. Dheda , A. D. Douglas , C. J. A. Duncan , K. R. W. Emary , K. Ewer , A. Flaxman , L. Fairlie , S. N. Faust , S. Feng , D. M. Ferreira , A. Finn , E. Galiza , A. L. Goodman , C. M. Green , C. A. Green , M. Greenland , C. Hill , H. C. Hill , I. Hirsch , A. Izu , D. Jenkin , S. Kerridge , A. Koen , G. Kwatra , R. Lazarus , V. Libri , P. J. Lillie , N. G. Marchevsky , R. P. Marshall , A. V. A. Mendes , E. P. Milan , A. M. Minassian , A. C. McGregor , Y. Farooq Mujadidi , A. Nana , S. D. Payadachee , D. J. Phillips , A. Pittella , E. Plested , K. M. Pollock , M. N. Ramasamy , H. Robinson , A. V. Schwarzbold , A. Smith , R. Song , M. D. Snape , E. Sprinz , R. K. Sutherland , E. C. Thomson , M. Torok , M. Toshner , D. P. J. Turner , J. Vekemans , T. L. Villafana , T. White , C. J. Williams , A. V. S. Hill , T. Lambe , S. C. Gilbert , A. Pollard , Group, Oxford COVID Vaccine Trial, Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine (2021), (available at https://papers.ssrn.com/abstract=3777268).

5. Hagai Rossman, Patterns of covid-19 pandemic dynamics following deployment of a broad national immunization program (2021), (available at https://github.com/hrossman/Patterns-of-covid-19-pandemic-dynamics-following-deployment-of-a-broad-national-immunization-program).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3